Microplastics/nanoplastics released from facemasks as contaminants of emerging concern.

Facemasks have become a global medical necessity and are a key preventive measure against COVID-19. Typically, facemasks (FMs) are fabricated from non-renewable polymers, particularly polypropylene (PP) and polyethylene (PE), which release secondary microplastic (MPs) due to the chemical, physical, and biological processes. In light of the widespread usage and improper disposal of single-use facemasks, there is concern about their environmental impact since they contribute to plastic pollution during and after pandemics. The repercussions of this have led to millions of tons of plastic waste being dumped into the environment. Due to lack of awareness and improper disposal, the occurrence of micro/nanoplastics released from facemasks in wastewater treatment plants and landfills poses a concern. Infiltration of wastewater treatment processes by micro/nanoplastics at various levels can be problematic because of their chemical nature and broad but small size. Thus, operational and process stability issues can arise during wastewater treatment processes. In addition, landfilling and illegal waste disposal are being used to dispose of potentially infectious COVID-19 waste, leading to an environmental threat to animal and human health and exacerbating plastic pollution. This paper reviews the fate of facemasks in the environment and the repercussions of improper waste management of facemasks in wastewater treatment plants, landfills, and ultimately the environment.

Efficacy of packed red blood cell transfusions based on weight versus formula in thalassemic children: An open-label randomized control trial.

BACKGROUND: Protocols for transfusion therapy in transfusion-dependent thalassemia (TDT) children differ among various medical centers. In India, most centers consider only the patient's weight while calculating the volume of packed red blood cells (PRBCs) to be transfused. This study aimed to compare the efficacy of PRBC transfusions of different volumes calculated either by weight or by a formula using weight and pretransfusion hemoglobin of patient and hematocrit of PRBC. STUDY DESIGN AND METHODS: Sixty TDT patients in the age group of 3-9 years were enrolled and randomly allocated to two groups. Group A received PRBC transfusion volume based on the patient's weight, and Group B received PRBC volume calculated using a formula for 6 months. RESULTS: Average pretransfusion hemoglobin in Group A and Group B (9 ± 0.4 vs. 8.9 ± 0.4 g/dl) was not significantly different (p = .353). Although the average number of visits in 6 months was less for Group A compared to Group B (7 ± 1 vs. 8 ± 1; p = .001); the average volume transfused per visit was more (351 ± 78 vs. 287 ± 68 ml; p = .003). The calculated average annual pure red cell requirement of the patients was 178 ml/kg/year for Group A and 154 ml/kg/year for Group B (p = .000). Total donor exposures were significantly lower in Group B than Group A (11 ± 3 vs. 14 ± 3; p = .006). CONCLUSION: The number of donor exposures and annual pure red cell requirement was significantly lower in the formula-based group. Transfusions based on formula are recommended in TDT patients.